Lp-PLA 2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.

Autor:	Wihastuti TA; Department of Basic Science in Nursing, Faculty of Medicine, University of Brawijaya, Malang, East Java, Indonesia., Aini FN; Faculty of Medicine, University of Islam Malang, Malang, East Java, Indonesia.; Master Programme of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia., Tjahjono CT; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia., Sulfia YH; Master Programme of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia., Sholichah Z; Master Programme of Biomedicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia., Heriansyah T; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Aceh, Indonesia.
Jazyk:	angličtina
Zdroj:	Vascular health and risk management [Vasc Health Risk Manag] 2019 Nov 01; Vol. 15, pp. 503-508. Date of Electronic Publication: 2019 Nov 01 (Print Publication: 2019).
DOI:	10.2147/VHRM.S217904
Abstrakt:	Purpose: The aim of this study is to prove that type 2 diabetes mellitus can induce increasing inflammation marker in renal and that the provision of darapladib as Lp-LA2 Inhibitor agents can inhibit inflammation that were measured from the expression of IL-1B and IL-6- type cytokine in renal. This study also discusses the correlation between IL-1B and IL-6- type cytokine expression in renal. Methods: Thirty Sprague-Dawley (SD) rats were divided into three main groups; those are negative control group (NC), Type 2 Diabetes Mellitus group (T2DM) given high fat diet (HFD) with streptozotocin intraperitoneal injection (35mg/kg BW) and diabetes mellitus + darapladib group (DM + DP). Each group was treated within two serial treatment time: 8 weeks and 16 weeks. Expressions of IL-1B and IL-6- type cytokine in renal were the markers that we measured by immunofluorosense method. Results: The administration of darapladib can significantly decrease the expression of IL-1B- type cytokine (p ANOVA = 0.029, p < 0.005) measured in rats' renal both at weeks 8 and 16 in the T2DM group. The Expression of IL-6- type cytokine also showed a significant difference after treated with darapladib both at weeks 8 and 16 in T2DM group with p-value of ANOVA = 0.033, p < 0.005. The Pearson correlation showed a strong correlation (linear regression value was r 2 = 0.743). Conclusion: Our results show that atherosclerosis caused by inflammation in renal T2DM SD rats could be inhibited by the administration of darapladib. Competing Interests: The authors report no conflicts of interest in this work. (© 2019 Wihastuti et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu